DOCETAXEL (TAXOTERE(TM)) IN ADVANCED GASTRIC-CANCER - RESULTS OF A PHASE-II CLINICAL-TRIAL

Thirty-seven eligible patients, median age 59 years (range 37-72) and median performance status 1 (0-2), with advanced, untreated, measurabl e gastric carcinoma were given docetaxel, 100 mg m(-2) i.v. over 60 mi n without premedication, once every 3 weeks. Metastatic sites included the liver in 12 patients and retroperitoneal lymph nodes in 16. Eight of the 33 evaluable patients (24%) achieved a partial remission for a median of 7.5 months (3-11 +). An additional 11 patients had stabilis ation of disease. The patients received a median of four cycles of doc etaxel (range 1-8) for a total of 156 courses. Dose reduction was nece ssary in 30 cycles; 14 cycles were delayed a mean of 3 days. Haematolo gical toxicity consisted mainly of non-cumulative neutropenia, with a median nadir count of 0.35 x 10(9) I-1 (0.04-1.64) and eight episodes (5%) of leucopenic fever; non-haematological toxicities included alope cia, mild nausea and vomiting and allergic manifestations such as skin rash and pruritus. There were no drug-related deaths. Our data indica te that docetaxel is an active agent in advanced gastric cancer; furth er clinical investigations seem warranted.